THERMO FISHER SCIENTIFIC INC.
Ticker: TMOHealthcareMedical InstrumentsS&P 500The business
Thermo Fisher Scientific Inc. (NYSE: TMO) operates as the world leader in serving science, enabling customers to make the world healthier, cleaner and safer through an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services. The company maintains its website at thermofisher.com.
The company serves a diverse customer base including pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial and quality control settings. Thermo Fisher operates through four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Life Sciences Solutions provides reagents, instruments and consumables for biological and medical research, drug discovery and vaccine production, encompassing biosciences, genetic sciences and bioproduction businesses. Analytical Instruments offers chromatography, mass spectrometry, chemical analysis and electron microscopy solutions for pharmaceutical, biotechnology, academic and industrial markets. Specialty Diagnostics delivers diagnostic test kits, reagents, culture media and instruments across clinical diagnostics, immunodiagnostics, microbiology and transplant diagnostics. Laboratory Products and Biopharma Services combines self-manufactured and sourced laboratory products with comprehensive outsourced services for pharmaceutical and biotech industries, including drug development, clinical research and commercial manufacturing.
The company operates under industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. As of December 31, 2025, Thermo Fisher employed approximately 125,000 colleagues globally, distributed across the Americas with 59,000 employees, Asia-Pacific with 22,000 employees, and Europe, the Middle East and Africa with 44,000 employees. The company maintains approximately 14,000 sales personnel including highly trained technical specialists.
Thermo Fisher pursues growth through organic investments in research and development, capacity expansion and strategic acquisitions. The company recorded significant goodwill and indefinite-lived intangible assets totaling approximately 49.36 billion and 1.23 billion dollars respectively as of December 31, 2025, reflecting its acquisition-driven growth strategy. The company's competitive advantages derive from technical performance, product differentiation, service quality, active research programs and reputation as a quality provider.
- Sector
- Healthcare
- Industry
- Medical Instruments
- HQ
- WALTHAM, MA
- FY end
- 12-31
- CIK
- 97745
- SIC
- 3829
Ownership
Who holds THERMO FISHER SCIENTIFIC INC. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.26% | $5.91B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.29% | $4.83B |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.29% | $2.56B |
| Fidelity 500 Index Fund FXAIX · Fidelity Concord Street Trust | 0.28% | $2.37B |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust SPY | 0.29% | $2.26B |
Superinvestors in THERMO FISHER SCIENTIFIC INC.
Share of each manager's reported 13F portfolio.
Bonds held by funds
Funds report holding 36 issues of THERMO FISHER SCIENTIFIC INC.'s debt, $2.39B at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 4.17%, maturing 2026–2049.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | 4.902% | 2036-02-12 | 131 | $299.00M |
| THERMO FISHER | 4.215% | 2031-02-12 | 75 | $219.97M |
| Thermo Fisher Scientific, Inc. | 4.473% | 2032-10-07 | 63 | $179.73M |
| Thermo Fisher Scientific Inc | 4.550% | 2033-06-15 | 94 | $166.33M |
| THERMO FISHER | 2.000% | 2031-10-15 | 43 | $147.08M |
| Thermo Fisher Scientific Inc | 4.794% | 2035-10-07 | 47 | $143.78M |
| Thermo Fisher Scientific Inc | 5.086% | 2033-08-10 | 60 | $130.38M |
| TMO 2.6 10/01/29 | 2.600% | 2029-10-01 | 50 | $109.63M |
| TMO 4.8 11/21/27 | 4.800% | 2027-11-21 | 40 | $88.38M |
| Thermo Fisher Scientific Inc | 4.200% | 2031-03-01 | 44 | $88.32M |
The 10 largest by fund-held value, of 36.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of THERMO FISHER SCIENTIFIC INC.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free